Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:35:05 23/01/2026 GMT			5-day change	1st Jan Change
217.72 ^USD	-0.18%		+1.62%	-4.67%

01-20	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-20	Berenberg Lifts Price Target on AbbVie to $275 From $270, Keeps Buy Rating	MT

Press Releases

01-19	AbbVie Announces Topline Results for Epcoritamab (DuoBody(R) CD3xCD20) from Phase 3 EPCORE(R) DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	AQ
01-16	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	PR
01-12	AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans	PR
01-12	AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors	PR
01-12	West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie	PR
01-07	AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call	PR
01-06	MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus	AQ
01-05	AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference	PR
12-02	AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers	PR
11-28	SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance	GL
11-25	AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec	GL
11-25	AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec	AQ
11-24	AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference	PR
11-19	AbbVie Announces U.S. FDA Approval of EPKINLY in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma	AQ
11-18	AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma	PR
11-17	LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer	AQ
11-14	AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer	PR
11-13	AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™	PR
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	PR
31/10/25	AbbVie : ABBV 3Q25 Press Release Final	PU
31/10/25	AbbVie: Q3 Earnings Snapshot	AQ
31/10/25	AbbVie Reports Third-Quarter 2025 Financial Results	PR
30/10/25	AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib in Adults and Adolescents with Vitiligo	AQ
30/10/25	ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers	AQ
29/10/25	The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Press Releases

Filters